Current and historical daily PE Ratio for Hepion Pharmaceuticals Inc (
) from 2016 to May 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hepion Pharmaceuticals stock (FRA:336) PE ratio as of May 26 2024 is 0.
More Details
Hepion Pharmaceuticals Inc (FRA:336) PE Ratio (TTM) Chart
Hepion Pharmaceuticals Inc (FRA:336) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1208
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Hepion Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-26 | At Loss | 2023-12-12 | At Loss |
| 2024-02-14 | At Loss | 2023-12-11 | At Loss |
| 2024-02-13 | At Loss | 2023-12-08 | At Loss |
| 2024-02-12 | At Loss | 2023-12-07 | At Loss |
| 2024-02-09 | At Loss | 2023-12-06 | At Loss |
| 2024-02-08 | At Loss | 2023-12-05 | At Loss |
| 2024-02-07 | At Loss | 2023-12-04 | At Loss |
| 2024-02-06 | At Loss | 2023-12-01 | At Loss |
| 2024-02-05 | At Loss | 2023-11-30 | At Loss |
| 2024-02-02 | At Loss | 2023-11-29 | At Loss |
| 2024-02-01 | At Loss | 2023-11-28 | At Loss |
| 2024-01-31 | At Loss | 2023-11-27 | At Loss |
| 2024-01-30 | At Loss | 2023-11-24 | At Loss |
| 2024-01-29 | At Loss | 2023-11-23 | At Loss |
| 2024-01-26 | At Loss | 2023-11-22 | At Loss |
| 2024-01-25 | At Loss | 2023-11-21 | At Loss |
| 2024-01-24 | At Loss | 2023-11-20 | At Loss |
| 2024-01-23 | At Loss | 2023-11-17 | At Loss |
| 2024-01-22 | At Loss | 2023-11-16 | At Loss |
| 2024-01-19 | At Loss | 2023-11-15 | At Loss |
| 2024-01-18 | At Loss | 2023-11-14 | At Loss |
| 2024-01-17 | At Loss | 2023-11-13 | At Loss |
| 2024-01-16 | At Loss | 2023-11-10 | At Loss |
| 2024-01-12 | At Loss | 2023-11-09 | At Loss |
| 2024-01-11 | At Loss | 2023-11-08 | At Loss |
| 2024-01-10 | At Loss | 2023-11-07 | At Loss |
| 2024-01-09 | At Loss | 2023-11-06 | At Loss |
| 2024-01-08 | At Loss | 2023-11-03 | At Loss |
| 2024-01-05 | At Loss | 2023-11-02 | At Loss |
| 2024-01-04 | At Loss | 2023-11-01 | At Loss |
| 2024-01-03 | At Loss | 2023-10-31 | At Loss |
| 2024-01-02 | At Loss | 2023-10-30 | At Loss |
| 2024-01-01 | At Loss | 2023-10-27 | At Loss |
| 2023-12-29 | At Loss | 2023-10-26 | At Loss |
| 2023-12-28 | At Loss | 2023-10-25 | At Loss |
| 2023-12-27 | At Loss | 2023-10-24 | At Loss |
| 2023-12-25 | At Loss | 2023-10-23 | At Loss |
| 2023-12-22 | At Loss | 2023-10-20 | At Loss |
| 2023-12-21 | At Loss | 2023-10-19 | At Loss |
| 2023-12-20 | At Loss | 2023-10-18 | At Loss |
| 2023-12-19 | At Loss | 2023-10-17 | At Loss |
| 2023-12-18 | At Loss | 2023-10-16 | At Loss |
| 2023-12-15 | At Loss | 2023-10-13 | At Loss |
| 2023-12-14 | At Loss | 2023-10-12 | At Loss |
| 2023-12-13 | At Loss | 2023-10-11 | At Loss |
Hepion Pharmaceuticals Inc (FRA:336) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Hepion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US21234W2026
Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers